Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on the current and emerging treatments for multiple myeloma discussed at ASH 2020. Immunomodulatory therapies such as bispecific T-cell engagers (BiTEs) and CAR T-cells are showing deep and durable responses, even among relapsed/refractory patients. While immunomodulatory drug and proteasome inhibitor combinations and transplants are still the standard of care, the future may see sequential use of immunotherapies to restore a memory immune response against myeloma, which may have curative potential. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть